Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada [3] - Phathom markets vonoprazan in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including heartburn associated with Non-Erosive GERD and H. pylori infection treatment [3] Upcoming Events - Members of Phathom's management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 12, 2026 [1] - The conference will take place from February 11-12, 2026, in New York, NY, and will include one-on-one meetings [2] - A live webcast and archived recordings of the event will be available on Phathom's website for 90 days following the meeting [2]

Market Overview - U.S. stock futures declined on Thursday after a mixed close on Tuesday, with only the Nasdaq 100 index ending in positive territory [1] - The Dow Jones futures fell by 0.29%, S&P 500 by 0.23%, Nasdaq 100 by 0.30%, and Russell 2000 by 0.45% [2] - The 10-year Treasury bond yielded 4.15%, while the two-year bond was at 3.47% [2] - The CME Group's FedWatch tool indicates an 88.4% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stocks in Focus - AZZ Inc. (NYSE:AZZ) shares rose by 2.8% in premarket trading after reporting strong third-quarter earnings [6] - Immuneering Corp. (NASDAQ:IMRX) shares fell by 22.93% following the announcement of updated survival and safety data from its Phase 2a trial for pancreatic cancer [6] - Northrop Grumman Corp. (NYSE:NOC) shares increased by 6.84% after President Trump proposed raising the 2027 military budget from $1 trillion to $1.5 trillion [6] - Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) shares dropped by 14.22% after announcing a $130 million public offering [14] - Constellation Brands Inc. (NYSE:STZ) shares rose by 2.32% after reporting better-than-expected third-quarter earnings [14] Economic Insights - Economist Paul Krugman warns that the Trump administration's economic policies may pose risks to the broader economy and stock market, suggesting that the market is pricing in unrealistic revenue streams [10][11] - Krugman highlights the potential disconnect between market exuberance and economic fundamentals, predicting a painful correction as the "oil fantasy" dissipates [12]

Group 1 - Phathom Pharmaceuticals, Inc. announced a public offering of 6,875,000 shares of common stock priced at $16.00 per share, along with pre-funded warrants for 1,250,078 shares priced at $15.999 each, aiming for gross proceeds of approximately $130 million before expenses [1][2] - The offering is expected to close on or about January 9, 2026, pending customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 1,218,761 shares at the public offering price [1] Group 2 - The net proceeds from the offering will be used for general corporate purposes, including working capital and expenses related to commercialization and research and development [2] - Guggenheim Securities and Cantor are acting as joint bookrunning managers, with Raymond James, Needham & Company, H.C. Wainwright & Co., and Craig-Hallum serving as co-managers for the offering [2] Group 3 - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases, including the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker [5] - Vonoprazan is marketed in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Core Viewpoint - Phathom Pharmaceuticals, Inc. plans to conduct an underwritten public offering of its common stock or pre-funded warrants, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The company intends to offer shares of its common stock or pre-funded warrants to certain investors [1] - The offering is subject to market conditions and other factors, with no assurance on completion or terms [1] - A shelf registration statement was filed with the SEC on January 7, 2026, which became effective automatically [3] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including working capital and R&D expenses [2] Group 3: Company Background - Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases [5] - The company has exclusive rights to vonoprazan, a potassium-competitive acid blocker, in the U.S., Europe, and Canada [5] - Vonoprazan is marketed in the U.S. for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Financial Results Announcement - Phathom Pharmaceuticals, Inc. announced preliminary unaudited financial results for Q4 and full year 2025 on January 7, 2026[4]. - A press release detailing the financial results is attached as Exhibit 99.1[6]. - The financial results include key metrics that will be elaborated in the press release[4]. Compliance and Listing Information - The company is listed on The Nasdaq Global Select Market under the symbol PHAT[2]. - The report is filed under the SEC regulations, indicating compliance with the Securities Exchange Act of 1934[5].

Core Insights - Phathom Pharmaceuticals, Inc. reported preliminary unaudited financial results for Q4 and full year 2025, indicating significant revenue growth and operational milestones [1][6]. Group 1: Preliminary Financial Results - For Q4 2025, Phathom expects net revenues of approximately $57 million to $58 million, with GAAP operating expenses of approximately $59 million to $61 million and non-GAAP operating expenses of approximately $51 million to $53 million, excluding about $8 million of stock-based compensation [8]. - For the full year 2025, net revenues are anticipated to be around $174.5 million to $175.5 million, with GAAP operating expenses of approximately $315.5 million to $317.5 million and non-GAAP operating expenses of approximately $284.5 million to $286.5 million, excluding about $31 million of stock-based compensation [8]. Group 2: Product Milestones - Phathom surpassed one million prescriptions dispensed for VOQUEZNA products in the U.S. since its launch during Q4 2025 [4]. Group 3: Future Outlook - The company anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation [5].

Summary of Phathom Pharmaceuticals FY Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Date of Conference**: December 02, 2025 Key Points Strategic Changes - Phathom has undergone significant changes in its operational strategy over the past year, focusing on sales calls to gastroenterologists as the primary revenue driver [5][3] - The company has reduced cash operating expenses by nearly 50%, from $360 million to $180 million, while maintaining sales force size and compensation [6][5] Sales and Marketing Strategy - The previous strategy focused heavily on primary care physicians and direct-to-consumer (DTC) advertising, which was deemed ineffective [8][9] - The current strategy emphasizes targeting gastroenterologists, who represent a more productive sector for prescriptions, as 70% of scripts come from this group [12][13] - The company has shifted away from DTC advertising, believing it does not significantly impact prescription rates [11][10] Revenue Performance - In Q3, Phathom reported approximately $50 million in revenue, with IQVIA TRX up about 17%, indicating potential for growth heading into the next quarter [15][18] - The company expects to maintain a trajectory towards profitability, with guidance suggesting positive operating profit by 2026 [33][34] Patient and Physician Engagement - The focus on gastroenterologists allows for more effective patient engagement, as these physicians treat patients who have failed previous therapies [10][27] - The company aims to create a positive feedback loop where satisfied patients advocate for the product to their primary care physicians, potentially increasing future prescriptions [28][26] Future Outlook - Phathom anticipates a revenue run rate of approximately $230 million by the end of the year, with consensus estimates for next year around $320 million, indicating a need for over 40% growth [18][19] - The company is exploring opportunities for over-the-counter (OTC) conversion of its product, which could extend market reach post-exclusivity [38][37] Financial Metrics - The company is committed to keeping expenses below $55 million for Q4, with expectations for stable operating expenses into 2026 [33][34] - Analysts suggest potential earnings power of $3-$5 per share in the future, contingent on sales growth [36][35] Additional Insights - The majority of prescriptions are for the higher 20 mg dose, indicating a focus on more severe cases of gastroesophageal reflux disease (GERD) [29][30] - The company is still in the early stages of evaluating long-term patient persistence on the medication, with initial data suggesting good refill rates [31][32] Conclusion Phathom Pharmaceuticals is strategically pivoting towards a more focused sales approach targeting gastroenterologists, which has led to significant cost reductions and a path towards profitability. The company is optimistic about future revenue growth and is exploring additional market opportunities, including OTC conversion.

Group 1 - Phathom Pharmaceutical's Voquezna and Voquezna Triple Pak are gaining market share in the U.S. GERD and H. pylori infection treatment markets [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]

Group 1 - Phathom Pharmaceutical's Voquezna and Voquezna Triple Pak are gaining market share in the U.S. GERD and H. pylori infection treatment markets [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]

Summary of Phathom Pharmaceuticals Conference Call Company Overview - **Company**: Phathom Pharmaceuticals - **Product**: VOQUEZNA, a next-generation treatment for gastroesophageal reflux disease (GERD) licensed from Takeda, which has shown significant success in Japan [2][4] Market Opportunity - **Target Market**: Focus on the 30%-40% of GERD patients who are on PPIs (Proton Pump Inhibitors) but still experience symptoms [3][6] - **Revenue Growth**: Achieved $55 million in revenue in 2024, with guidance for $170-$175 million in 2025 [3] - **Gastroenterology Focus**: Shifted strategy to concentrate on gastroenterology, which is expected to drive growth over the next few years [3][19] Competitive Landscape - **Market Positioning**: VOQUEZNA is not positioned as a direct competitor to PPIs; it is intended for patients who have failed prior PPI therapy [12][13] - **Prescription Opportunity**: There are approximately 20 million PPI prescriptions written annually by gastroenterologists, representing a significant market for VOQUEZNA [7][9] Sales Strategy - **Sales Force Reallocation**: 70% of sales efforts are now focused on gastroenterologists, up from 30% previously targeting primary care [19][21] - **Productivity Metrics**: Sales calls to gastroenterologists yield four times the productivity compared to primary care [21] Exclusivity and Regulatory Strategy - **Exclusivity Timeline**: VOQUEZNA has exclusivity through May 2032, with potential extensions into 2034 depending on ongoing trials and FDA reviews [28][29] - **GAINS Act Utilization**: The company successfully leveraged the GAINS Act to extend exclusivity for the product [27] Financial Projections - **Revenue Potential**: Aiming for $1 billion in revenue from the gastroenterology market, with a clear path to achieving this through increased market penetration [10][36] - **Growth Rate Stability**: The company has maintained a stable growth rate despite the transition in sales strategy [24][44] Coverage and Access - **Insurance Coverage**: VOQUEZNA is covered by over 80% of commercial lives, with varying requirements for prior PPI failures [17][46] - **Cash Pay Strategy**: The company is also focusing on cash pay prescriptions to ensure patient access, which can later convert to covered prescriptions [53][56] Patient Experience and Persistence - **Patient Retention**: Early data suggests strong persistence rates for patients switching to VOQUEZNA, driven by significant symptom relief [42][40] - **Long-term Outlook**: The company anticipates that positive patient experiences will lead to sustained prescription growth over time [57] Conclusion - Phathom Pharmaceuticals is strategically positioned to capture a significant share of the GERD treatment market through VOQUEZNA, with a focused sales strategy, strong revenue growth, and a clear path to exclusivity that supports long-term financial success [36][58]